Philip Morris
Fields
- Author
- Klarberg, R.B.
- Area
- SELIGMAN,ROBERT
- Type
- LETT, LETTER
- Copied
- R, S.
- Seligman, R.B.
- S, R.B. <Seligman, R.B.>
- Seligman, R.B.
- Request
- Stmn/R1-004
- Stmn/R1-149
- Recipient
- Seligman, R.B.
- Document File
- 1003710125/1003710305/American Heath Foundation. Missing
- Litigation
- Stmn/Produced
- Author (Organization)
- Ahf, American Health Foundation
- Master ID
- 1003710268/0270
Related Documents: - Characteristic
- MARG, MARGINALIA
- Site
- R35
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- szw97e00
Document Images
AM E RIiCAN H EALTH FOUN
320 East'43rd Street; New York, New YOrk,1D01'7 (212) 4894700
Naylor Dana Institute
for Disease Prevention
Valhalla, NJY. 10595
Pho ne: 9,1 tl,-592=2ti00
R 11: CEI V E D
MAY 17 1978
R. B. SELIGMAN May U, 1978
OFFICERS AND
BOARD OFTRUSTEES
David J. Mahoney, Chairman
Chairman and Chief'Executive Offlcer
Norton Simond Inc.
William J. Levitt, Past Chairman
Founder-Chairman
LevitY3'Sons, Inc.
Ernst L. Wynder, M.D., Presitlent'
John D. Twiname, ManagingDlrector
Eric M. Javita; Secretary
Senior Partner
Javits 6,Javits
Warner G. Cosgrove, Jt., Treasurer
TRUSTEES:
John J. Burns. Ph.D. "`
Vice President fon Research
Hoffmann+La Roche;, Inc.
Thomas L. Chrystie
Senior Vice President
Merrill Lynch & Co. Inc.
Mrs. Charles A: Dana
D. Ronald Daniel
Managing Director,
; McKinsey A' Company, Inc.
Ralph Landau, Sc.D.
Chairman & Chief'Executive Officer
Halcon International, Inc.
5, Hildegard E. Merrill
Joseph Robbie
Managing Partner
Miami Dolphins. Ltd.
:John W.Simmns
`.Presidenf8 Chief'Executive Officer
Morton-Norwich Products, Inc.
Mrs. Jennifer Jones Simon
;.. Thomas A. WAtson
ADM. E.,R. Zumwalt;,Jr>, USN(Ret.)',
David L. Davies
Executive Vice President
JohniH. Weisburger, Ph.D.
Vice PresJdentfor Research
~
DATION
Robert B. Seligman, Ph.D.
Vice-President, Research and Deve].opment.
PhiliplNlorris Research Center
Richmond~, V'irginia,
Dear Dr. Seligman,
I am pleased to enclose an executed
assignment of patent agreement regarding scaven-
ger reactions of NOX.
Please note that in Paragraph 2 1 added
a statement to clarify the fact that the assign-
ment is'applicable only to research in this area
which has been funded by your company.
Looking forward to see'ing you soon
again, I am
RBK/mh
-ficerely,
R~ ~ch rd B. I~~
S~ le al Counse
